Arovella Therapeutics Limited · ASX:ALA

Arovella Therapeutics — Shareholder Meeting (October 2021)

16 slides from Arovella Therapeutics's shareholder meeting presentation, Oct 14, 2021

1. Slide 1: Presentation to Shareholders

   SUDA Presentation to Shareholders 14 October 2021 © Copyright SUDA Pharmaceuticals Ltd 2021

2. Slide 2: Board & Senior Management

   Board & Senior Management Chairman CEO and MD Executive Director Director Director Paul Hopper Dr. Michael Baker David Phillips David Simmonds Dr. Debora Barton Over 25 years experience in Over 15 years experience in Senior Business Development David was a senior audit Over 20 years of oncology the

3. Slide 3: Agenda

   Agenda • Managing Director’s address • Q&A (via online platform) • Formal Business © Copyright SUDA Pharmaceuticals Ltd 2021

4. Slide 4: Progress in 2021

   Progress in 2021  ZolpiMist® commercialization (Teva, STADA, other territories) – Australian partner secured  Integrate and develop new technologies – iNKT cell therapy platform acquired  Anagrelide formulation stabilisation  Early-stage feasibility development work Regulatory Sales Feasibility

5. Slide 5: ZolpiMist - Insomnia

   ZolpiMist® - Insomnia  ZolpiMist is SUDA’s oral spray version of the insomnia drug Ambien/Stilnox, Sanofi’s blockbuster1  Short-term insomnia has an estimated prevalence of 9.5% in the US2  Sleep problems rose from 16% to 25% during the COVID-19 pandemic (University of Southampton)3  STADA to co

6. Slide 6: iNKT Cell Therapy Platform – Highlights (acquired June 2021)

   iNKT Cell Therapy Platform – Highlights (acquired June 2021) SUDA’s invariant Natural Killer T (iNKT) cell therapy platform is at the forefront of immuno-oncology drug development Pre-clinical studies show that:  CAR-iNKT cells work more efficiently than conventional cell therapies  CAR-iNKT cells

7. Slide 7: SUDA's iNKT Cell Therapy Platform

   SUDA’s iNKT Cell Therapy Platform iNKT Cell Benefits  iNKT cells are one of the most potent types of immune cells, Healthy Donor acting rapidly  iNKT cells bridge the adaptive and innate immune system  iNKT cells activate components of the immune system to fight cancer cells  The iTCR is common

8. Slide 8: What are Chimeric Antigen Receptors (CARs)?

   What are Chimeric Antigen Receptors (CARs)? iNKT Cell CD19-CAR CAR19-iNKT Cell Cancer Cell CD19 The iNKT cells are Immune cells are Once administered to the genetically re- harvested from the cancer patient, the CAR-iNKT programmed with a CAR, healthy donor and the cells can seek out and destroy sup

9. Slide 9: Different CARs to Target Different Cancers or Diseases

   Different CARs to Target Different Cancers or Diseases CD19 CAR 1 Blood Cancers CAR 2 Solid Tumours CAR 3 Other Diseases 9 © Copyright SUDA Pharmaceuticals Ltd 2021

10. Slide 10: CAR-iNKT Cell Therapy Development 24 months

    CAR-iNKT Cell Therapy Development 24 months  Recruit cell therapy manufacturing expert – Dr. Sandhya Buchanan   Enter into Research Agreement with Imperial College London   Recruit domain expertise board members – Dr. Debora Barton   Expand Scientific Advisory Board – Prof. Tassos Karadimitri

11. Slide 11: iNKT Cells Can Be Used Off The Shelf

    iNKT Cells Can Be Used Off The Shelf While this news is unfortunate for Allogene, and others working with T cells to create allogeneic cell therapy products, this may be an advantage for SUDA’s iNKT cell therapy technology. iNKT cells do not need additional gene editing to be used off the shelf. The

12. Slide 12: Shareholder Support to Transform the Company

    Shareholder Support to Transform the Company “SUDA has undergone several transformations over its 22-year history. In order to fully realise our potential, we believe it is important to revitalise our image to enable our key stakeholders to see us from a fresh perspective. We have in- licenced what

13. Slide 13: Q&A

    Q&A 13 | © Copyright SUDA Pharmaceuticals Ltd 2021

14. Slide 14: Special Business Resolutions

    Special Business Resolutions Resolutions 1. Approval of change of Company name 2. Ratification and approval of previous allotment and issue of Shares 3. Approval of Employee Share Option Plan 4. Approval of allotment and issue of options to a related party: Dr. Michael Baker 5. Approval of issue of

15. Slide 15: Contact

    CONTACT Dr. Michael Baker CEO & Managing Director Email: mbaker@sudapharma.com Mobile: +61 403 468 187 © Copyright SUDA Pharmaceuticals Ltd 2021

16. Slide 16: Disclaimer

    Disclaimer 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Suda Pharmaceuticals Limited (Company). In prepar

Arovella Therapeutics — Shareholder Meeting (October 2021) on 6ix